In EGJ adenocarcinoma, the FGF-FGFR2 signaling axis may be a crucial pathway in tumor progression; thus, this cancer may be adequately managed by an FGFR2-specific inhibitor. The gene discussed is FGFR2; the disease is neoplasm.